Royal Bank of Canada »

Rapport Therapeutics shares owned by Royal Bank of Canada

Quarter-by-quarter ownership of Rapport Therapeutics shares owned by Royal Bank of Canada from 13F filings

Historical chart of Royal Bank of Canada investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Royal Bank of Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Royal Bank of Canada

Quarter filed Position value Share count Share price at filing
2024-06-30 $5.0k 225 22.22

More positions owned by Royal Bank of Canada

Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Amazon (AMZN)
Toronto Dominion Bk Ont Com New (TD)
Rbc Cad (RY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Core S&p500 Etf (IVV)
Alphabet Cap Stk Cl A (GOOGL)
Bank Of Montreal Cadcom (BMO)
JPMorgan Chase & Co. (JPM)
Bk Nova Cad (BNS)
Enbridge (ENB)
Visa Com Cl A (V)

View all positions for Royal Bank of Canada

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
T. Rowe Price Associates
Alliancebernstein
Perceptive Advisors
Citadel Advisors
Artal Group
Logos Global Management
Woodline Partners
Millennium Management
TD Asset Management
Manufacturers Life Insurance Company

View all funds holding Rapport Therapeutics